Monitoring measurable residual disease (MRD) via liquid biopsy is a method for catching early-stage cancer and disease relapse long before traditional diagnostics, which generally require significant disease progression for detection.
Assays in development include those that target patient-specific variants and fixed panels for all patients. Regardless, detection of variant allele frequencies at extremely low levels, well below the limit of detection of typical circulating tumor DNA (ctDNA) assays, presents a challenge that can be surmounted with well-designed reference materials that allow for assessment of sensitivity and specificity.
This poster from LGC SeraCare presents data supporting the use of the Seraseq ctDNA MRD Panel kit, composed of four tumor fractions at decreasing levels, to validate both patient-specific and fixed-panel targeted cfDNA NGS MRD assays.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences